Перейти к основному содержанию
AkademIndex

Продукты

Для разработчиков

AkademBaseОткрытый API экосистемы
Статья

Efficacy of statins in familial hypercholesterolaemia: a long term cohort study

Jorie VersmissenDepartment of Internal Medicine, Erasmus University Medical Centre, PO box 2040, 3000 CA Rotterdam, NetherlandsDaniëlla M. OosterveerDepartment of Internal Medicine, Erasmus University Medical Centre, PO box 2040, 3000 CA Rotterdam, NetherlandsMojgan YazdanpanahDepartment of Internal Medicine, Erasmus University Medical Centre, PO box 2040, 3000 CA Rotterdam, NetherlandsJoep C. DefescheDepartment of Vascular Medicine, Academic Medical Centre, PO box 22660, 1100 DD Amsterdam, NetherlandsDick C.G. BasartDepartment of Cardiology, Westfries Gasthuis, PO box 600, 1620 AR Hoorn, NetherlandsAnho LiemJan HeeringaDepartment of Epidemiology and Biostatistics, Erasmus University Medical Centre, RotterdamJ. C. M. WittemanDepartment of Epidemiology and Biostatistics, Erasmus University Medical Centre, RotterdamPeter LansbergDepartment of Vascular Medicine, Academic Medical Centre, PO box 22660, 1100 DD Amsterdam, NetherlandsJ.J.P. KasteleinDepartment of Vascular Medicine, Academic Medical Centre, PO box 22660, 1100 DD Amsterdam, NetherlandsEric J.G. SijbrandsDepartment of Internal Medicine, Erasmus University Medical Centre, PO box 2040, 3000 CA Rotterdam, Netherlands
2008en
ABI

Аннотация

OBJECTIVE: To determine the efficacy of statin treatment on risk of coronary heart disease in patients with familial hypercholesterolaemia. DESIGN: Cohort study with a mean follow-up of 8.5 years. SETTING: 27 outpatient lipid clinics. SUBJECTS: 2146 patients with familial hypercholesterolaemia without prevalent coronary heart disease before 1 January 1990. MAIN OUTCOME MEASURES: Risk of coronary heart disease in treated and "untreated" (delay in starting statin treatment) patients compared with a Cox regression model in which statin use was a time dependent variable. RESULTS: In January 1990, 413 (21%) of the patients had started statin treatment, and during follow-up another 1294 patients (66%) started after a mean delay of 4.3 years. Most patients received simvastatin (n=1167, 33 mg daily) or atorvastatin (n=211, 49 mg daily). We observed an overall risk reduction of 76% (hazard ratio 0.24 (95% confidence interval 0.18 to 0.30), P<0.001). In fact, the risk of myocardial infarction in these statin treated patients was not significantly greater than that in an age-matched sample from the general population (hazard ration 1.44 (0.80 to 2.60), P=0.23). CONCLUSION: Lower statin doses than those currently advised reduced the risk of coronary heart disease to a greater extent than anticipated in patients with familial hypercholesterolaemia. With statin treatment, such patients no longer have a risk of myocardial infarction significantly different from that of the general population.

Перевод пока недоступен

Идентификаторы

Цитирования и источники

Цитирований: 2Использованных источников: 0